breast cancer. Family history of malignant neoplasm of breast
Conditions
Interventions
Intervention 1: The intervention group will receive a pill of Ginkgo biloba (40 mg), three times a day for 2 weeks. Participants who tolerate the pills will receive them at a dose of 80 mg three times
Treatment - Drugs
Placebo
The intervention group will receive a pill of Ginkgo biloba (40 mg), three times a day for 2 weeks. Participants who tolerate the pills will receive them at a dose of 80 mg three times a day for the r
The control group will receive pills of placebo that look like Ginkgo biloba tablet, following the same regimen as the intervention group.
Sponsors
Mashhad University of Medical Sciences, Vice chancellor for research
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Being married;18 years of age or older; At least 2 month after the end of treatment; Signed and dated written informed consent prior to admission to the study;The ability to speak; understand the Persian; Patients who had undergone breast cancer surgery Exclusion criteria: not having sex at least twice during the study period; Having any other medical; conditions such as: cardiovascular diseases ( i.e. uncontrolled hypertension, history of infarction, deep-vein thrombosis), Pulmonary diseases (i.e. asthma, shortness of breath), Neurological diseases ( i.e. convulsions, epilepsy, migraine, cerebrovascular disorder), History of bleeding disorder, kidney diseases, liver diseases, endocrine disorders (i.e. diabetes), mental disorders, coagulation disorders; Other malignancies other than breast cancer; Infertility; Stressful event (other than cancer) during the last 6 months (e.g. traumatic and stressful event, changes in living conditions such as relocation, financial ruin, marital problems, losing a close family member); Failing to follow the treatment plan; A history of psychiatric disorder; Patients taking SSRI 2 weeks prior to study; Anticoagulant therapy (Heparin, enoxaparin, warfarin, clopidogrel, ticlopidine) 2 weeks prior to study; Patients with hormone-receptor (HR)-positive breast cancer.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Female Sexual Function Index score. Timepoint: Before and after intervention. Method of measurement: Female Sexual Function Index scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Homaee Shandiz
Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Outcome results
None listed